Find policies, billing codes, payers, states, and providers
Cardiovascular Disease Risk Assessment
Customize your policy alerts
Sign up for all Oscar Health policy alerts
Know when Oscar Health releases new policies or updates existing guidance.
Monitor payer policy activity
Defines coverage, frequency, and limitations for laboratory testing and biomarkers used to assess cardiovascular disease (CVD) risk for Oscar Health members, and indicates who and when testing is covered.
SCORE2 is recommended in apparently healthy people <70 years of age without established ASCVD, diabetes, CKD, or genetic/rare lipid or blood pressure disorders for estimation of 10-year fatal and non-fatal CVD risk.
Presence of subclinical coronary atherosclerosis by imaging or increased CAC score by CT is recommended as a risk modifier to improve risk classification for individuals at moderate risk or near treatment thresholds.
In primary prevention, pharmacological LDL-C lowering therapy recommendations specified LDL-C thresholds for very high, high, moderate and low risk groups using explicit LDL-C values.
Lp(a) measurement should be considered at least once in each adult person's lifetime to identify those with very high inherited levels (>180 mg/dL) that confer lifetime ASCVD risk comparable to heterozygous familial hypercholesterolemia.
Coverage Criteria for Cardiovascular Risk Assessment Tests
Lipid panel: Initial and monitoring criteria
Covered when ANY of the following are met for lipid panel testing (simple lipid panel defined in Note 1):
see Note 1 for simple lipid panel components
10-year ASCVD risk cannot be calculated for individuals 39 years of age or younger
conditions listed in policy
includes transplant patients and HIV-positive individuals
ApoB and Lp(a) coverage
Covered biomarkers and frequencies:
listed clinical indications; NLA supports role for apoB
NLA/CCS/ESC recommend one-time measurement
Not medically necessary / Not covered tests
Not covered for CVD risk assessment:
DOES NOT MEET CRITERIA
DOES NOT MEET CRITERIA
DOES NOT MEET CRITERIA; refer to other policies for non-CVD indications
DOES NOT MEET CRITERIA
DOES NOT MEET CRITERIA; clinical utility lacking
DOES NOT MEET CRITERIA
policy: NOT covered unless specified
Cardiovascular risk panels/profiles
Proprietary cardiovascular risk panels and multi-marker profiles
Examples include Genova Cardio Check™ and Cleveland HeartLab CVD Inflammation Testing Profile
ACC/AHA guideline recommendations
Guideline-based use of biomarkers to refine ASCVD risk assessment
CIMT not recommended routinely; contribution of some markers (ApoB, Lp(a), CKD, albuminuria, fitness) is uncertain
Risk-enhancing biomarker cutoffs
Specific biomarker thresholds considered risk-enhancing by guideline authors
ApoB measurement may be considered when triglycerides ≥ 200 mg/dL; Lp(a) relatively indicated with family history of premature ASCVD
ADA guidance
ADA recommendations relevant to testing and monitoring in diabetes
Children with T1D/T2D have specific lipid screening timing recommendations
Recommended testing scenarios
Coverage-relevant testing and monitoring described by guidelines (situations when measurement is recommended):
NLA and AACE/ACE recommendations
ADA, NLA, CMS guidance
NLA and 2024 update support one‑time measurement
NLA supports role for ApoB
CDC/AHA workshop recommendations
Guideline-based consideration statements
Guideline statements indicating when CVD risk assessment or BP screening may be considered
ESC/EAS guideline phrasing 'may be considered'
Applies to opportunistic screening context
Recommendation context preserved from ESC/EAS excerpts
Opportunistic screening
Covered when ALL of the following are met according to ESC/EAS guidance excerpts:
Repeat screening after 5 years or sooner if risk close to treatment thresholds
ESC/EAS 2025 focused update recommendations (primary prevention)
Recommendations and decision rules from ESC/EAS 2025 focused update for primary prevention and lipid testing:
Class I, Level B in guideline excerpts
Class IIa, Level B
Screen at least once per adult lifetime
Use after optimizing non‑pharmacological measures
Convenient and does not require fasting
When testing or imaging is recommended
Guideline-based recommendations and scenarios where testing or imaging may be considered
CCS and ESC/EAS recommend a one‑time measurement for risk identification
ApoB convenient and not fasting‑dependent; preferred in certain metabolic states
Several societies endorse CAC for reclassification; some recommend against routine use in high‑ or low‑risk groups
ESC, EASD, Endocrine Society and others note limited incremental value
Multiple guidelines indicate five‑year intervals
Not routinely recommended
Guidance recommending against routine testing
VA/DoD and other bodies suggest against routine use; USPSTF finds insufficient evidence to add ABI, hs‑CRP, or CAC to traditional risk assessment in asymptomatic adults
ASCP and other organizations discourage routine expanded lipid testing
The policy lists multiple individual biomarkers and multi-analyte panels that DO NOT MEET CRITERIA for cardiovascular disease risk assessment. Examples explicitly named include conventional or high-sensitivity CRP, high-sensitivity cardiac troponin T (hs-cTnT), homocysteine, cystatin C, BNP/NT‑proBNP, apolipoproteins (eg, apoAI), fibrinogen, leptin, LDL/HDL subclasses, myeloperoxidase, and long-chain omega‑3 fatty acid measurement in red blood cell membranes. The policy further states that proprietary multi‑biomarker CVD risk panels (combinations of these markers reported together) also DO NOT MEET CRITERIA because their clinical utility and impact on patient management are lacking.
The document notes that Cystatin C has been proposed as a marker related to inflammation and obesity and as an indicator of impaired kidney function, which is itself a CVD risk factor. However, it states there is no published literature proving Cystatin C’s effectiveness for predicting cardiovascular risk in the excerpts provided and that Cystatin C is not routinely used as a CVD biomarker.
Commercial cardiovascular risk panels that combine multiple lipids, inflammatory, genetic, and metabolic markers are discussed but the policy makes clear the clinical utility is lacking. The policy explains that these panels report multiple individual tests and/or use proprietary algorithms, yet their impact on clinical management is unknown and therefore they are not supported as routine tools for CVD risk assessment.
Guidance cited in the policy emphasizes that hs‑CRP may be measured as an adjunct in selected, metabolically stable patients (optimally measured twice about two weeks apart) but the CDC/AHA recommends against screening the entire adult population for hs‑CRP as a public health measure. Consistent with that position, the policy states CRP (conventional or high‑sensitivity) DOES NOT MEET CRITERIA for routine CVD risk assessment.
Some guideline excerpts included in the policy do not contain explicit exclusions within those particular sections. The policy preserves the original guideline language in these excerpts and does not add additional coverage exclusions beyond those stated elsewhere in the document.
Other extracted guideline passages likewise do not include explicit coverage exclusions in the text fragments shown. These excerpts focus on recommendations for opportunistic screening intervals and risk‑assessment contexts rather than listing specific tests as excluded.
The ESC/EAS guidance quoted in the policy specifically notes that routine measurement of Apo C‑III is not recommended because its clinical utility is unknown; the guideline therefore recommends against routine Apo C‑III testing for risk assessment.
Guideline text describes the role and limits of coronary artery calcium (CAC) scoring: CAC can be helpful as a risk modifier to improve classification for individuals at moderate risk or near treatment thresholds, but several societies (eg, CCS) recommend that CAC screening not be undertaken for high‑risk individuals, patients already on statin therapy, or most asymptomatic low‑risk adults. Thus CAC is presented as a selective reclassification tool rather than a general screening test.
The policy includes a regulatory note about laboratory‑developed tests (LDTs): many LDTs are developed and validated in‑house and are regulated by CMS under CLIA as high‑complexity tests. LDTs are not FDA‑approved or cleared, and while FDA clearance is not required for clinical use, this regulatory status is noted in the document.
Certain extracted reference sections in the document contain only bibliographic entries or publication history and do not include explicit coverage criteria, medical‑necessity statements, or exclusions within those particular chunks.
In addition to the individual markers already named, the policy excerpt lists other biomarkers and assays discussed in the evidence and commercial panels, including myeloperoxidase, Lp‑PLA2, oxidized LDL, ADMA/SDMA, microalbumin, and multi‑component proprietary tests. The policy treats these additional biomarkers as part of the broader group of novel or multi‑marker tests that generally DO NOT MEET CRITERIA for routine CVD risk assessment unless specifically covered elsewhere.
The policy references meta‑analysis data on isotretinoin indicating that although isotretinoin can change mean laboratory values (including lipid measures) in treated patients, the proportion of patients with clinically meaningful abnormalities was low, and the authors concluded these data do not support routine monthly laboratory testing for standard acne dosing. The excerpt is cited to explain monitoring context rather than to endorse routine CVD biomarker testing.
The document states that elevated homocysteine has been associated with increased CVD risk but also notes that clinical trials lowering homocysteine have not demonstrated clear reductions in cardiovascular events. Consequently, routine measurement of homocysteine for CVD risk assessment is not consistently recommended and is considered of unproven clinical utility in this context.
The CDC/AHA workshop cited in the policy concluded that hs‑CRP measurement may be reasonable as an adjunct in selected, metabolically stable patients (optimally measured twice about two weeks apart), but it recommended against population‑wide screening for hs‑CRP. The policy mirrors that stance by not supporting hs‑CRP as a routine screening test for all adults.
The extracted evidence reference list and publication history sections do not contain statements classifying tests as not medically necessary; they serve as supporting citations and record governance approval of the document on 06/16/2026.
Other scattered evidence or reference excerpts included in the document do not contain explicit not‑medically‑necessary (NMN) determinations within those chunks; the policy’s NMN conclusions are stated in the coverage and exclusions sections elsewhere in the document.
The policy references the 2021 ESC guidance noting that C‑reactive protein provides limited additional value and that Lp(a) has limited reclassification potential in some contexts. The document therefore reflects that routine use of CRP or broad novel biomarkers adds only limited incremental predictive value and should be used selectively.
Consistent with multiple guideline statements included in the policy, routine assessment of novel circulating or urinary biomarkers for CVD risk stratification is not recommended because they generally provide limited additional clinical value and have not been shown to change management or outcomes in most asymptomatic individuals.
Several extracted chunks do not contain determinations about not‑medically‑necessary status; where NMN conclusions are intended, they are stated explicitly in the policy coverage, exclusion, and not‑medically‑necessary sections rather than in reference or evidence list fragments.
Procedure and Test Coding
| 80061 | Lipid panel |
| 81599 | Unlisted multianalyte assay with algorithmic analysis |
| 82172 | Apolipoprotein, each |
| 82465 | Cholesterol, serum or whole blood, total |
| 82610 | Cystatin C |
| 83090 | Homocysteine |
| 83695 | Lipoprotein (a) |
| 83718 | Lipoprotein, direct measurement; high density cholesterol (HDL cholesterol) |
| 83721 | Lipoprotein, direct measurement; LDL cholesterol |
| 83722 | Lipoprotein, direct measurement; small dense LDL cholesterol |
| 84478 | Triglycerides |
| 84484 | Troponin, quantitative |
| 84512 | Troponin, Qualitative |
| 84999 | Unlisted chemistry procedure |
| 85384 | Fibrinogen; activity |
| 85415 | Fibrinolytic factors and inhibitors; plasminogen activator |
| 86140 | C-reactive protein |
| 0019M | Lipoprotein, blood, high resolution fractionation and quantitation (proprietary VAP test) |
| SOMAmer (proprietary) | Cardiovascular disease protein biomarker aptamer-based panel (SomaLogic) — proprietary test referenced |
| VAP Cholesterol Test (proprietary) | Vertical auto profile ultracentrifugation proprietary test (VAP Diagnostics) |
| Liposcale (proprietary) | NMR-based lipoprotein profile (CIMA Sciences) |
| SmartHealth Vascular Dx (proprietary) | Proprietary multi-marker immunoassay with algorithm (Morningstar Laboratories) |
| HDL Reverse Cholesterol Transport Panel (proprietary) | Quest Diagnostics proprietary test reporting pCAD score |
Provider Actions, Documentation, and Authorization
Verify member benefits before ordering tests
Application of the policy criteria depends on the member's benefit coverage at the time of the request; Medicare and Medicaid specifications are found in the ‘Applicable State and Federal Regulations’ section and must be followed when applicable.
- Verify member benefits and any applicable government coverage (LCDs/NCDs or state Medicaid rules) before ordering tests.
No prior authorization specified in excerpt
The excerpted policy does not specify any prior authorization requirements for the tests and biomarker measurements described.
PA not specified for guideline-recommended biomarkers
No prior authorization requirements for biomarker testing are stated in the guideline excerpts; guideline language focuses on when measurements are recommended rather than payer PA rules.
No PA requirements in guideline excerpts
The guideline excerpts do not state any prior authorization requirements for lipid or biomarker testing.
No PA requirements in this excerpt
No prior authorization requirements are stated in the provided excerpt of this policy.
PA not specified for these sections
This document excerpt does not specify prior authorization requirements for the listed cardiovascular risk assessments or tests.
No PA requirements stated
No prior authorization requirements are described in the provided excerpts for the tests and biomarkers discussed.
Follow guideline LDL‑C thresholds for therapy decisions
The ESC/EAS guideline specifies LDL-C thresholds by risk category for considering or recommending pharmacological LDL-C–lowering therapy (examples: very high risk recommend therapy at LDL-C ≥1.8 mmol/L [70 mg/dL]; consider therapy at ≥1.4 mmol/L [55 mg/dL] for very high risk; high risk recommend at ≥2.6 mmol/L [100 mg/dL]; see guideline thresholds for full numeric cutpoints).
- Use the guideline numeric LDL‑C cutpoints by overall risk category when discussing pharmacologic therapy decisions.
- Apply thresholds only after optimizing non‑pharmacological measures, per guideline text.
Follow applicable government coverage determinations
If there is a conflict between this policy and an applicable government coverage determination (e.g., Medicare LCD/NCD or state Medicaid), the government policy governs the determination; providers must follow those rules for authorization and coverage decisions.
- Check the Medicare Coverage Database and relevant state Medicaid resources for current government policy when applicable.
Verify PA requirements for listed procedure and proprietary codes
The policy lists CPT/HCPCS and proprietary procedure codes (examples: 80061, 82172, 83695, 84478, 86140, 0019M and various proprietary panel identifiers). Providers should verify any payer-specific prior authorization requirements for these codes before ordering.
- Confirm PA requirements for listed CPT/HCPCS and proprietary test codes in the payer's authorization system prior to submission.
No PA requirements in this section
No prior authorization requirements are specified in this section of the excerpted policy.
No action specified in excerpt
(No specific provider action stated in the excerpted inventory placeholder.)
No step therapy sequences specified
No step‑therapy sequences or mandated therapeutic sequencing are specified in the provided excerpts.
No mandated step‑therapy for biomarkers
Guideline excerpts describe use of additional biomarkers to inform treatment decisions after traditional risk estimation and clinician–patient discussion, but do not mandate step‑therapy sequences.
No step therapy requirements in guideline excerpts
No step‑therapy rules are specified in the guideline excerpts provided.
No step therapy described in this excerpt
The provided excerpts do not describe step‑therapy requirements for biomarker testing or imaging.
No step therapy requirements present
No step‑therapy requirements for testing are specified in these excerpts of the policy.
Step therapy not specified
No step‑therapy sequences are specified in the policy excerpts for the tests and biomarkers discussed.
Initiate pharmacologic therapy after optimizing lifestyle measures
Pharmacological LDL‑C‑lowering therapy recommendations in the guideline apply after optimization of non‑pharmacological measures; providers should document attempts at lifestyle modification prior to initiating therapy when appropriate.
- Ensure non‑pharmacological measures have been optimized before initiating pharmacological LDL‑C lowering per guideline language.
Consider CAC to guide lipid‑lowering therapy in intermediate‑risk patients
Consider coronary artery calcium (CAC) scoring by CT to help reclassify risk and inform initiation or intensification of lipid‑lowering therapy in patients at intermediate or moderate ASCVD risk when treatment decisions are uncertain.
- Do not use CAC routinely in high‑risk patients, patients already on statin therapy, or most low‑risk asymptomatic adults per guideline/CCS recommendations.
No action specified
(Inventory placeholder; no action specified in extracted text.)
No step therapy rules in extracted chunks
(No step‑therapy rules are present in these extracted chunks.)
Document services and code claims accurately
Providers must submit accurate documentation of services performed and code claims appropriately according to industry-standard coding guidelines; failure to follow coding/billing guidelines or to provide sufficient documentation may result in claim denial or recoupment.
- Document clinical indication, test ordered, laboratory results, and rationale for testing in the medical record to support medical necessity.
- Code claims according to CPT/HCPCS and payer-specific guidance and verify coding before submission.
Record evidence-based rationale for monitoring
The document summarizes clinical trial and meta‑analysis contexts relevant to monitoring (e.g., statin response variability and isotretinoin lipid changes) that support the need for monitoring in specific therapies; include monitoring rationale in documentation when ordering tests.
- When ordering monitoring based on drug therapy (e.g., statins, isotretinoin), document the therapy and clinical reason for testing in the chart.
Obtain baseline and 4–12 week lipid monitoring after statin start
When initiating statin therapy obtain a baseline fasting lipid panel and repeat testing 4–12 weeks after initiation or dose change to assess adherence and response; thereafter repeat measurements every 3–12 months as clinically indicated.
- Document baseline and follow‑up lipid results and any medication changes to support medical necessity of subsequent tests.
Ensure laboratory reports flag extreme/ actionable lipid values
Laboratory reports should denote desirable values and specifically identify extremely elevated LDL‑C (≥190 mg/dL in adults or ≥160 mg/dL in children) and actionable abnormalities such as fasting triglycerides ≥500 mg/dL; CDC Lipids Standardization Program certification may be used to demonstrate laboratory accuracy.
- Ensure lab reports highlight LDL‑C and TG thresholds and include method and fasting status where relevant.
Timing: measure LDL‑C 4–6 weeks after therapy initiation/intensification
Measure LDL‑C 4 to 6 weeks after initiation or intensification of lipid‑lowering therapy per ESC/EAS guidance; ApoB and ApoA‑I measurements are convenient and do not require fasting and may be used as alternatives per guideline text.
- Use ApoB/ApoA‑I as an alternative when triglycerides are high or fasting not feasible.
Obtain baseline lipid profile and population‑specific follow‑up tests
Obtain a baseline lipid profile (TC, HDL, non‑HDL, triglycerides) prior to treatment; for some populations (e.g., renal transplant patients) measure TC, HDL and LDL after 3 months of therapy and monitor transaminases at baseline, 3 months, and 12 months where indicated.
- Record baseline transaminases where statin initiation is planned in transplant patients and follow the specified follow‑up intervals.
Align documentation and coverage decisions with government policies
Providers should reference and follow applicable Medicare/Medicaid LCDs/NCDs and state Medicaid policies when they differ from this policy; documentation should support alignment with those government policies.
- Check the Medicare Coverage Database and relevant state Medicaid resources for current determinations prior to ordering when government coverage applies.
Claims may be denied if coding or documentation is insufficient
Claims may be denied or recouped if coding/billing guidelines or current reimbursement policies are not followed and documentation is insufficient to support medical necessity.
- Ensure clinical documentation includes diagnosis, indication for test, therapy status, and follow‑up plan to substantiate medical necessity.
Proprietary cardiovascular risk panels risk denial without demonstrated utility
Commercial proprietary multi‑marker cardiovascular risk panels lack demonstrated clinical utility and their impact on patient management is unknown; tests reported as panels may be discouraged for coverage and risk denial if clinical utility is not shown.
- Provide clear clinical rationale and supporting documentation if ordering proprietary panels; expect potential denial when clinical utility is not documented.
Document rationale for frequent lipid monitoring to avoid denial
CMS guidance allows more frequent lipid testing (up to six times in the first year) when monitoring long‑term anti‑lipid therapy; if monitoring frequency outside standard intervals is claimed, document the clinical rationale to avoid denial.
- Document reasons for increased monitoring frequency (e.g., marked lipid elevations, therapy changes, inadequate response) to support medical necessity.
Background and Scope
Background: The policy frames cardiovascular risk assessment around the use of standard lipid panels and selective biomarkers to estimate a person’s risk of CVD events and to guide clinical decision‑making. It notes that traditional risk algorithms may miss a proportion of events and that biomarkers and imaging can be used selectively as risk modifiers, but many novel tests show only modest incremental predictive ability.
Definitions and Key Terms
Policy Revision History
Policy effective date set to 2026-10-01.
Last review and governance approval recorded on 2026-06-16.
ESC/EAS 2025 focused update recommendations (use of SCORE2, CAC as risk modifier, LDL‑C cutpoints, and one-time Lp(a) screening) were added to guideline-based considerations included in the policy.
National Lipid Association (NLA) / related expert consensus evidence (ApoB guidance and Lp(a) measurement recommendations) from 2024 were incorporated into coverage rationale and testing frequency statements.
Publication and change history: this policy’s publication history notes governance approval on 06/16/2026 and the evidence/reference sections cited in the document provide the supporting literature behind the policy statements and coverage determinations.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.